Strengthens firm’s mental property portfolio with improvements in subsequent era single entry RAS expertise
TORONTO, Sept. 22, 2022 (GLOBE NEWSWIRE) — Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical machine firm targeted on the event and commercialization of modern surgical applied sciences for single entry robotic-assisted surgical procedure (RAS), right this moment introduced the publication of worldwide patent utility No. PCT/CA2022/050392, which the corporate anticipates pursuing in the US and different key markets beneath the Patent Cooperation Treaty (PCT).
The patent utility usually discloses dexterous endoscope applied sciences to be used with RAS methods which are designed to offer a sturdy workspace subject of view larger than these supplied by prior endoscope applied sciences, that are designed to seize solely a portion of a surgical web site. Know-how described within the patent utility may very well be utilized in a wide range of single entry RAS methods, together with these designed to assist three devices which are concurrently positionable inside an insertion conduit.
“It was vital for us to share the publication of this patent utility because it highlights our continued dedication to be an innovation chief in single entry RAS, which incorporates but additionally extends past the present growth of the Enos™ surgical system,” mentioned Cary Vance, President and CEO of Titan. “Whereas we’re targeted on the event, scientific and regulatory actions for the Enos system, we’re dedicated to persevering with to advance the surgical expertise for sufferers, surgeons and hospitals via the analysis and growth of RAS expertise parts and methods. Submitting patent functions on our innovations stays an vital step in defending the worth we proceed to generate, together with these designed for next-generation applied sciences and methods. As we additional innovate and develop our RAS expertise roadmap, we count on to increase our management in single entry innovation and mental property, competitively positioning Titan, notably with respect to imminent RAS entrants.”
Titan has developed an expansive mental property portfolio with over 220 pending and issued patents protecting the US and different jurisdictions that assist and canopy numerous points of single-access RAS together with the Enos system’s surgeon workstation, affected person cart, dexterous articulating devices, ergonomic hand-controllers, enhanced imaginative and prescient methods, superior management software program, and instinctive surgeon overlays for offering interoperative suggestions. This protection of single-access RAS, and particularly the Enos system, together with protection of extra common points of RAS applied sciences, might present the corporate with a number of mental property choices together with additional defending its RAS applied sciences, and the potential to additional license its applied sciences and help in securing a aggressive business pathway.
About Titan Medical
Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical machine firm headquartered in Toronto, Ontario with operations in Chapel Hill, North Carolina, is targeted on enhancing robotic assisted surgical procedure (RAS) utilizing modern expertise via a single entry level. The Enos™ robotic single entry surgical system is being developed with an ergonomic focus to offer a surgical expertise that imitates real-life actions that surgeons demand and contains multi-articulating devices designed to permit surgeons an elevated vary of movement in a confined house, with dexterity and the power to exert the forces vital to finish widespread surgical duties. With the Enos system, Titan intends to initially pursue gynecologic surgical indications.
Enos™ is a trademark of Titan Medical Inc.
This information launch accommodates “forward-looking statements” inside the which means of relevant Canadian and U.S. securities legal guidelines, which mirror the present expectations of administration of the corporate’s future development, outcomes of operations, efficiency and enterprise prospects and alternatives. Ahead-looking statements are incessantly, however not at all times, recognized by phrases corresponding to “might”, “would”, “might”, “will”, “anticipate”, “consider”, “plan”, “count on”, “intend”, “estimate”, “potential for” and comparable expressions, though these phrases is probably not current in all forward-looking statements. Ahead-looking statements that seem on this launch might embody, with out limitation, references to: the corporate’s plans beneath the PCT; the potential benefits of the corporate’s applied sciences together with dexterous endoscope applied sciences offering a sturdy workspace subject of view; the expertise described within the patent utility being utilized in a wide range of single entry RAS system; the corporate’s dedication to being an innovation chief in single entry RAS, which incorporates but additionally extends past the Enos system; the corporate’s dedication to advance the surgical expertise for sufferers, surgeons and hospitals; the corporate’s expectation to increase its management in single entry improvements and mental property; the corporate’s aggressive place, together with with respect to imminent RAS entrants; the protection of and the choices supplied by the corporate’s mental property portfolio; the Enos robotic single entry surgical system being developed with an ergonomic focus to offer a surgical expertise that imitates real-life actions that surgeons demand; and that Titan intends to initially pursue gynecologic surgical indications. These statements mirror administration’s present beliefs with respect to future occasions and are based mostly on data at present obtainable to administration. Ahead-looking statements contain vital dangers, uncertainties and assumptions. Many elements might trigger the corporate’s precise outcomes, efficiency or achievements to be materially completely different from any future outcomes, efficiency or achievements that could be expressed or implied by such forward-looking statements, together with, with out limitation, these listed within the “Threat Components” part of the corporate’s Annual Report for the fiscal yr ended December 31, 2021 which can be considered at www.sedar.com and at www.sec.gov. Ought to a number of of those dangers or uncertainties materialize, or ought to assumptions underlying the forward-looking statements show incorrect, precise outcomes, efficiency, or achievements might range materially from these expressed or implied by the forward-looking statements contained on this information launch. These elements needs to be thought of rigorously, and potential traders shouldn’t place undue reliance on the forward-looking statements. Though the forward-looking statements contained within the information launch are based mostly upon what administration at present believes to be affordable assumptions, the corporate can’t guarantee potential traders that precise outcomes, efficiency or achievements shall be in keeping with these forward-looking statements. Besides as required by regulation, the corporate expressly disclaims any intention or obligation to replace or revise any forward-looking statements whether or not on account of new data, future occasions or in any other case.
Vice President, Investor Relations
& Company Communications